ArticleCell reports2017
Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.
Article in Cell reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.Hepatology (Baltimore, Md.) · 2026Article
- Advancing liver cancer immunotherapy beyond checkpoint blockade.Science China. Life sciences · 2026Article
- PolyIC as an adjuvant outperforms anti-VEGF in combination with anti-PD-L1 therapy in mouse liver tumor models.Hepatology communications · 2025Article
- First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors.Frontiers in pharmacology · 2025Article
- Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.Pharmaceutics · 2023Article
- Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.Hepatology (Baltimore, Md.) · 2022Article
- Two distinct Notch signals, Delta-like 4/Notch1 and Jagged-1/Notch2, antagonistically regulate chemical hepatocarcinogenesis in mice.Communications biology · 2022Article
- Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.Cell reports · 2021Article
- Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.Expert opinion on therapeutic targets · 2021Review
- Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.Cellular & molecular immunology · 2021Review
- Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.Hepatology (Baltimore, Md.) · 2021Review
- Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer.Journal for immunotherapy of cancer · 2021Review
- Review
- Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Review
- Genetically Engineered Mouse Models for Liver Cancer.Cancers · 2019Review
- Review
- An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice.Hepatology (Baltimore, Md.) · 2019Article
- Tumor immunology and immunotherapy: a journey I started from Hangzhou.Journal of Zhejiang University. Science. B · 2019Article
- AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.Cancer prevention research (Philadelphia, Pa.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Liver cancer has become the second most deadly malignant disease, with no efficient targeted or immune therapeutic agents available yet. While dissecting the roles of cytoplasmic signaling molecules in hepatocarcinogenesis using an inducible mouse gene targeting system, Mx1-cre, we identified a potent liver tumor-inhibitory effect of synthetic double-stranded RNA (dsRNA), polyinosinic-polycytidylic acid (pIC), an inducer of the Mx1-cre system. Injection of pIC at the pre-cancer stage robustly suppressed liver tumorigenesis either induced by chemical carcinogens or by Pten loss and associated hepatosteatosis. The immunostimulatory dsRNA inhibited liver cancer initiation, apparently by boosting multiple anti-tumor activities of innate immunity, including induction of immunoregulatory cytokines, activation of NK cells and dendritic cells, and reprogramming of macrophage polarization. This study paves the way for the development of preventive and early interfering strategies for liver cancer to reduce the rapidly increasing incidences of liver cancer in an ever-growing population with chronic liver disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.